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Background: Long-acting-b-agonists and inhaled corticosteroids are widely used in patients
with obstructive lung disease. We determined the occurrence of potential side effects to
inhaled steroids and long-acting-b-agonists in an open post-marketing observational study.
Methods: A total of 158 adult patients treated with long-acting-b-agonists and inhaled steroids
because of asthma or chronic obstructive lung disease were included prospectively in a cross-
sectional study from September 2004 through august 2005. A subgroup of 31 patients with
minimal disease were observed prospectively after treatment reduction. The frequency and
intensity of potential side effects to long-acting-b-agonists and inhaled corticosteroids were
registered on a 10-point visual analogue scale.
Results: A total of 131 (83%) reported potential side effects to inhaled steroids. The most
frequent were sore (54%) and dry (52%) throat. A total of 114 (72%) patients reported potential
side effects to long-acting-b-agonists. The most frequent were muscle cramps (62%) and
muscle twisting (39%). For 5/8 potential side effects their occurrence increased with increased
individual dozing. In 31 patients the mean medication with steroids and long-acting-b-agonists
was reduced by 87% and 97.5%, respectively, with side effects reduced by 62% (p< 0.001) to
inhaled steroids and by 91% (p< 0.001) to inhaled long-acting-b-agonists.
Conclusions: Potential side effects in adult patients to inhaled corticosteroids and long-acting-
b-agonists are very common with increased frequency with increased dozing. Patients are
largely unaware of the association. Patients should be better informed, and the results further
support tailored dozing to minimum therapy.
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Current guidelines in asthma medical treatment1 suggest
that adult patients with moderate or severe persistent
asthma should be treated with medium and high dose.
Potential side effects steroids and b2-agonists 567inhaled corticosteroids (ICS) in combination with long-
acting b2-agonists (LABA). Also in the pharmacological
treatment of chronic obstructive lung disease (COPD)
current guidelines2 suggest treatment with LABA in patients
with moderate and severe disease, and also the addition of
ICS in patients with severe COPD suffering from recurrent
acute exacerbations of chronic bronchitis (AECB). As both
diseases, persistent asthma and moderate to severe COPD
are very common in the adult populations this has led to
a widespread use of ICS and LABA. For the Danish adult
(40e70 years of age) population and for the two most
frequent used LABA (Salmeterol and Formoterol) the
treatment with LABA alone or in fixed combination with ICS
in general practice in 2005 was 111.3 defined daily doses
per 1000 individuals and per day where 33% were treated
with LABA alone and 67% received combination therapy
(Laegemiddelstyrelsen, personal communication). A
further 57.4 defined daily doses of ICS (Budesonide or Flu-
ticasone) per 1000 individuals per day were used in general
practice in Denmark in 2005, part of which were given in
combination with LABA.
The frequency of adverse drug reactions is addressed in
pre-marketing clinical trials to obtain approval for
marketing and in post-marketing studies.
The pre-marketing clinical trials are conducted under
the ethical and scientific quality standard good clinical
practice (GCP).3 These standards define adverse reactions
as any untoward medical occurrence in a patient partici-
pating in a clinical trial. These adverse reactions are ‘‘any
unfavourable and unintended sign, symptom or disease
temporally associated with the use of a medicinal
product’’.3 As such the adverse reactions reported spon-
taneously by the patients or noticed by the investigator
conducting the clinical trial are typical distinctive and
represent events that are most often qualitatively different
from events in normal life.
Potential adverse events occurring as changes in
frequency of events occurring in normal life are more diffi-
cult to associate with drug administration in clinical trials. A
recent review4 of the effects of LABA treatment in asthma
finds a slightly increased odds ratio of 1.35 for any drug
related adverse effects in 9 controlled trials with 2823
participants. The only individual side effect with a signifi-
cantly increased risk with LABA treatment was headache
(odds ratio 1.35 (95% confidence interval 1.01e1.81)).4
Likewise in a review5 on the effects and safety of treatment
with ICS in patients with COPD oral candidiasis, sore throat,
bruising and hoarseness were reported commonly in clinical
trials but the incidence was in most studies below 10%.
Pre-marketing trials intend to register all health events
during the period of therapy because any adverse event in
the pre-marketing phase of drug development can be
largely unknown. In contrast post-marketing analysis of
adverse events to a given therapy, which is best performed
as epidemiologic observational studies of patients who
receive drugs in clinical practice,6 can be performed much
more focused with more precise detection and quantifica-
tion of specific adverse events.
In the present study we interviewed a cohort of adult
outpatients already in treatment with a combination of
LABA and ICS for COPD or asthma with a registration of the
frequency, intensity and dose of relatively mild potentialside effects to treatment, just as a subgroup of patients
after a substantial reduction in treatment were interviewed
again after months for possible changes in the occurrence
of potential side effects.Material and methods
From September 1st 2004 and until August 30th 2005 all
adult outpatients seen by one of the authors (J.K.) and on
a daily treatment with inhalations of a combination of ICS
and LABA administered in either separate inhaler devices or
combined in a single inhaler device underwent a stand-
ardised interview on the frequency and intensity of phar-
macological predictable potential side effects to both
treatments.
Patients were treated with ICS and LABA because of
a clinical suspicion of asthma and/or chronic obstructive
lung disease (COPD), where all patients had received
treatment with the same daily dose in a period of at least 3
months prior to the interview. All patients treated with oral
steroids within the last 3 months were excluded.
The patients were interviewed as part of their routine
clinical assessment and patients were included consecu-
tively. No patients declined participation with a total of 158
adult patients included in the 12-month interval.
The pharmacological predictable potential side effects
to treatment with ICS were occurrence of a sore throat,
where the patient was asked if the patient or close family
had noticed a problem with a sore throat possibly with
a deeper voice. The patient was asked if he experienced
a dry throat in daily life, and if the patient had experienced
oral thrush within the last 3 months. Lastly was asked if the
patient had noticed skin bruises without a significant blow
to the skin site in question. The frequency of sore and dry
throat was counted as number of days per month where the
event had occurred, while frequency of oral thrush was
the mean number of days per month with oral thrush over the
last three months, and lastly skin bruises were the number
of days with one or more skin bruises within the last month.
The pharmacological predictable potential side effects
to treatment with inhalations of LABA were, whether the
patient had noticed any unwillingly spontaneous muscle
twisting with a special focus on the small muscles in the
lower eyelid. The patient was asked if the patient had
experienced occasions with muscle cramps in hands, toes
and foot and/or in the calves in the morning. The patient
was asked on the occurrence of hand tremor and lastly
asked on the experience of heart palpitations. For all four
LABA questions the frequency was the number of days per
month where the potential side effect had been noticed.
In cases where the individual patient confirmed on the
occurrence of specific potential side effects the patient
was asked, whether or not the patient was aware of the
possible association between treatment and the potential
side effect.
For all 8 specific potential side effects to treatment with
both ICS and LABA the intensity was judged by the patient
on a arbitrary 10-point visual analogue scale (VAS) where
the extremes were stated as 1 meaning a very slight and not
troublesome side effect and 10 was a very significant and
troublesome side effect in the patients’ daily life.
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effect the dose of the side effect was calculated by
multiplication of the two, and lastly all scores for ICS and
LABA were added to a total score of potential side effects
for each group.
A subgroup of 31 adult patients with, from the routine
clinical evaluation, minimal or no disease for which the
inhalation treatment in question was primarily given, were
either taken off treatment with ICS and LABA or had a very
substantial reduction in dosing. This subgroup of patients
was interviewed a second time on the same potential side
effect at least 3 months after treatment stop or reduction.
As it happened only two different ICS were encountered
in the 158 adult patients, where 84 patients were treated
with Budesonide and 74 were treated with Fluticasone
propionate. The individual doses were standardised in the
analysis, where a dose of 250 mg Fluticasone propionate was
equivalent to either 400 mg Budesonide (metered dose) or
320 mg Budesonide (delivered dose). In the present analysis
this 24-hour dose was given the ICS dosing value of 2. In the
group of patients almost 50% were treated with a dose of
ICS of 4 units or above, where 37% of patients were treated
with a dose of ICS of 8 daily doses, and 9.5% with 16 daily
doses (all with Fluticasone propionate) (Fig. 1).
As LABA treatment Formoterol and Salmeterol were
encountered, where again a daily dose unit of 1 was
standardised to a daily dose of 25 mg Salmeterol which was
equivalent to Formoterol 4.5 mg. The dose of LABA was less
variable, where 59% received 4 daily doses of LABA, while
17% received 8 daily doses (Fig. 1).
The systematic collection of data from patients was
approved by the Danish Data Protection Agency.
Results
The mean age of the 158 patients was 53 years (SDZ 17),
where the majority (91 (58%)) was women with no differ-
ence in mean age between gender.
Qualitatively more than half of patients reported the
occurrence of sore (54%) and/or dry (52%) throat on one or
more days in the last month in association with ICS treat-
ment (Table 1) and 35% had experienced skin bruises on one0
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Figure 1 The cumulative dosing for ICS and LABA among 158
adult patients interviewed on potential side effects to both
treatments. A dose of 1 for ICS corresponds to a dose of 125 mg
Fluticasone propionate or 160 mg Budesonide (inhaled dose) or
200 mg Budesonide (metered dose). A dose of 1 for LABA
corresponds to a dose of 25 mg Salmeterol or 4.5 mg Formoterol.or more days within the last three months, while only 11%
had experienced oral thrush within the last three months of
treatment. A total of 131 patients (83%) reported the
occurrence of one or more potential side effect in associ-
ation with ICS treatment (Table 1).
Most patients (67%) were aware of the fact that oral
thrush could be a potential side effect to treatment with
ICS, while only a minority (10e32%) were aware of any
throat problems in association to ICS therapy and only 13%
stated that ICS treatment could be a contributing etiologic
factor in relation to skin bruises.
Oral thrush and skin bruises were relatively rare events
in this population with a mean occurrence of 1 and 5 days
per months, respectively, just as the degree of nuisance
(mean VAS score of 0.8 and 1.4, respectively) was relatively
low. In contrast throat symptoms were both, as mentioned
above, very frequent and occurred as a more or less chronic
problem with a mean frequency (all 158 patients) of 15
days/month, just as throat symptoms were clearly the most
troublesome potential side effect for patients with a mean
VAS score of 3 (Table 1).
A total of 114/158 (72%) patients had experienced one or
more potential side effect to LABA treatment within the
last month, where the most frequent was the occurrence of
muscle cramps, which 62% of patients had experienced on
one or more occasions. Likewise about one third of patients
had experienced one or more occasions with unwillingly
muscle twisting (39%), hand tremor (34%) and heart palpi-
tations (34%). Only 21% and 28% of patients reporting events
with hand tremor and palpitations were aware of the
potential etiologic role of LABA treatment. Even less so
when patients were asked about the potential etiologic role
of LABA treatment in the genesis of unwilling muscle
twisting or muscle cramps, 0/61 (0%) and 6/98 (6%),
respectively, were aware of the possible association
between LABA treatment and the potential muscular side
effect (Table 2).
One or more cases of muscle cramps within the last
month were also the most frequent potential side effect,
and occurred in all patients with a mean frequency of twice
a week (Table 2) and for the 62% of patients actually
reporting cramps occurred with a mean frequency of four
times a week. From the score on VAS, muscle cramps were
again the most troublesome potential side effect with
a score of 3.6 (Table 2).
To further investigate the possible causal role of treat-
ment with ICS and LABA in the association to the potential
side effects the internal consistency was analyzed by
calculation of Pearson correlation coefficient between the
individual dozing of treatment and the dose (frequency
times intensity) of each single potential side effect. Except
for dry throat and ICS dozing, skin bruises and ICS dozing
and heart palpitations and LABA dozing there was a signifi-
cant association between increasing doses and an increased
occurrence of potential side effects (Tables 3 and 4).
As only two different steroids and two different LABA
were encountered among patients, it was possible to
analyze for generic differences between the two groups.
The 84 patients treated with Budesonide were treated with
a mean daily dose of 4 units compared to 8.7 units in 74
patients treated with Fluticasone propionate (p< 0.001).
As a probable consequence of the higher doses
Table 1 The frequency, intensity and resulting dose for four different potential side effects to treatment with ICS in 158 adult
patients treated with a combination of ICS and LABA.
Potential
side effect
Experienced by
(NZ 158) (%)
Known as
potential
side effect (%)
Frequency
(days/month)
Intensity (VAS) Dose (frequency times
intensity)
Mean Standard
deviation
Mean Standard
deviation
Mean Standard
deviation
Sore throat 85 (54) 27/85 (32) 14.8 14.8 2.7 3.1 75.7 91.6
Dry throat 82 (52) 18/82 (10) 13.2 14.4 3.0 3.5 79.7 103.0
Oral thrush 18 (11) 12/18 (67) 0.9 4.3 0.8 2.3 6.5 33.2
Skin bruises 56 (35) 7/56 (13) 4.9 9.2 1.4 2.6 27.1 68.8
ICS total 131 (83) e e e e e e e
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propionate the patients reported a higher occurrence of
sore throat and oral thrush (Table 5).
The two different LABA treatments were also dosed
differently as patients treated with Salmeterol were given
higher daily doses than patients treated with Formoterol
(Table 6). The slightly different dozing of the two types of
LABA did not reflect in the occurrence of potential side
effects, as there were no significant differences in the
occurrence of individual and total potential LABA side
effects between the two drugs (Table 6).
In 31 of the participating patients a substantial reduction
in medication could be achieved in relation to minimal or no
disease in question, and theywere interviewed a second time
after treatment stop or reduction. The mean ICS dozing was
3.9 daily units (NZ 31) before reduction, where 16 patients
completely stopped taking ICS while 15 patients all were
treated with a maximum of 1 daily unit of ICS with a mean for
all 31 patients of 0.5 daily units. Likewise the mean LABA
doses given before reduction were 4.2 daily doses where
LABA treatment was stopped in 29 patients and 2 patients
continued with a maximum dose of 1 daily unit with
a resulting mean of 0.07 daily units for all 31 patients.
When potential side effects were compared before and
after reduction in medication there was a marked reduction
in potential side effects (Fig. 2). For the total ICS dose of
the added four potential side effects, they were reduced
from a mean of 275.5 to a mean of 105.2 doses (frequency
times intensity) a reduction of 62%, where sore throat was
reduced with 74% (p< 0.001), dry throat was reduced with
47% (pZ 0.004), oral thrush was reduced with 79%Table 2 The frequency, intensity and resulting dose for four d
adult patients treated with a combination of ICS and LABA.
Potential
side effect
Experienced by
(NZ 158) (%)
Known as
potential
side effect (%)
Frequenc
(days/mo
Mean
Muscle twisting 61 (39) 0/61 (0) 2.2
Muscle cramps 98 (62) 6/98 (6) 7.8
Tremor 53 (34) 15/53 (28) 7.7
Heart
palpitations
53 (34) 11/53 (21) 4.4
LABA total 114 (72) e e(pZ 0.114) and lastly skin bruises were reduced with 54%
(pZ 0.052).
The potential side effects to LABA treatment were
reduced even more with reduction, where the total LABA
dose (frequency times intensity) was reduced from 193.2
before reduction to a score of 17.4 which is a reduction of
91% (Fig. 2). As to individual potential side effects muscle
twisting dose was reduced by 79% (pZ 0.034), muscle
cramps by 99% (p< 0.001), hand tremor by 81% (pZ 0.009)
and lastly heart palpitations were reduced by 98%
(pZ 0.009).
The occurrence of sore throat (Pearson correlation
coefficientZ 0.20 (p< 0.01)), the frequency of skin bruises
(Pearson correlation coefficientZ 0.21 (p< 0.01)) and the
total dose of potential side effects to ICS (Pearson corre-
lation coefficientZ 0.16 (p< 0.05)) increased significantly
with increased age of patients while the occurrence of
other potential side effects did not correlate with the age
of patients (data not shown). There was no difference
between the occurrence of side effects in association to
gender.
Discussion
The experiences on adverse events from large-scale clinical
trials on effects of ICS and LABA in patients with more or
less severe chronic asthma or COPD are dominated by
events closely related to the chronic disease in question.
In placebo controlled trials in patients with COPD and
treatment with ICS and LABA the most frequently reported
health event during study is respiratory infection7 withifferent potential side effects to treatment with LABA in 158
y
nth)
Intensity (VAS) Dose (frequency times
intensity)
Standard
deviation
Mean Standard
deviation
Mean Standard
deviation
5.7 1.4 2.4 11.4 37.5
10.8 3.6 3.6 52.8 85.2
12.5 1.6 2.8 40.3 79.2
9.0 1.7 2.9 26.0 61.7
e e e e e
Table 3 The doseeresponse relationship between the dose of four different potential side effects to treatment with ICS in 158
adult patients treated with a combination of ICS and LABA. The low doses were less than 4 units per day, medium doses were 4
but less than 8 doses per day and high doses were 8 doses per day where 2 units equals 250 mg Fluticasone propionate and
400 mg Budesonide (metered dose).
Potential
side effect
Dose inhaled corticosteroid Pearson correlation
coefficient
(NZ 158)
Low
mean (SEM)
(35)
Medium
mean (SEM)
(50)
High
mean (SEM)
(73)
Sore throat 69.0 (15.1) 35.0 (9.0) 106.8 (11.5) 0.26 (p< 0.001)
Dry throat 64.2 (17.1) 60.6 (12.7) 100.2 (12.8) 0.12 (pZ 0.135)
Oral thrush 2.3 (1.7) 0.7 (0.4) 12.4 (5.6) 0.18 (pZ 0.027)
Skin bruises 16.1 (6.6) 14.1 (5.5) 41.3 (10.7) 0.124 (pZ 0.123)
Total 151.1 (27.5) 110.4 (19.5) 260.1 (27.8) 0.246 (pZ 0.002)
570 J. Korsgaard, M. Ledeta frequency of 9e14%/year and upper respiratory tract
infection8,9 with a frequency of 9e17%/24 weeks. In the
same study only oral candidiasis is reported significantly
more frequent with ICS treatment (7e10%) compared to
placebo treatment (1%)8,9 in case of oral inspection while
Calverley et al.7 report a frequency on moniliasis on ICS
treatment in 2% of cases compared to 0e1% not treated
with ICS. Likewise throat irritation and hoarseness/
dysphonia occurred seldom (<10%), and with no difference
compared to placebo treatment. In one study10 skin bruises
were noted among 6% with placebo treatment and among
7e8% treated with ICS. Muscular events were not mentio-
ned7e10 in relation to adverse events.
Recent clinical trials on the effects of ICS and LABA in
asthma have compared different treatment regimes or
fixed dosing compared to adjustable dosing. Again the
reported health events are vastly dominated by events
related to the underlying chronic disease with frequencies
of mild to severe asthma exacerbations, often used as
primary efficacy variable, of 30%/6 months,11 16e25%/6
months12 and 32e62%/12 months13 to mention a few.
Another frequently reported health event is, as in studies
on COPD, respiratory infections with frequencies of 25%/12
weeks14 and 15e16%/6 months.15
In the same study with either presumably spontaneously
patient reported health events which is judged by the
investigator to be relevant11e15 or other studies with
spontaneous reported events or recorded in response toTable 4 The doseeresponse relationship between the doses of f
158 adult patients treated with a combination of ICS and LABA.
a medium dose was 4 units per day and a high dose was >4 units p
or 4.5 mg formoterol.
Potential
side effect
Dose long-acting b2-agonist
Low
mean (SEM)
(36)
Medium
mean (SE
(93)
Muscle twisting 3.5 (1.6) 9.3 (3.
Muscle cramps 40.3 (13.4) 49.7 (8.
Tremor 13.7 (6.3) 44.6 (8.
Heart palpitations 20.1 (8.3) 22.1 (5.
Total 67 (19.0) 116.2 (16a standard question of any health-related problems since
last visit16,17 the frequency of potential side effects to
treatment with ICS is rare with hoarseness and dry throat
only reported once11 with a frequency of 3 and 4%,
respectively, oral candidiasis either not reported14,17 or
with a frequency of 0e3%,11e13,15,16 dysphonia not repor-
ted11,17 or with a frequency of 1e4%13e16 or 1e7%.12 The
latter study12 is the only study reporting a group difference
on oral candidiasis and specific ICS treatment, while all
other studies11,13e17 do not find either any group differ-
ences or any doseeresponse relations between different
dosing regimes and the occurrence of potential side
effects. None of the studies mention skin bruises as
potential side effect to ICS treatment in asthma.
The data on potential side effects to treatment with LABA
in the same study11e17 is even more scarce with reported
frequency of tremor in only one case13 with a frequency of
2% and three studies13,15,16 report frequencies of heart
palpitations of 0e2%. Again no studies on asthma and LABA
treatment mention the occurrence of any muscular events
in their patient populations.
The present data on the frequency of potential side
effects to both ICS and LABA treatment shows a much more
frequent occurrence of side effects than in the mentioned
clinical trials. In fact for any of four different potential side
effects to ICS treatment 83% have experienced one or more
side effects to a different extend within the last three
months and likewise 72% of patients treated with LABAour different potential side effects to treatment with LABA in
A low dose of long-acting b2-agonists was <4 units per day,
er day where 1 unit corresponds to a dose of 25 mg salmeterol
Pearson correlation
coefficient
(NZ 158)M)
High
mean (SEM)
(29)
1) 28 (12.3) 0.22 (pZ 0.005)
5) 82.3 (17.9) 0.175 (pZ 0.033)
8) 59.8 (17.1) 0.181 (pZ 0.022)
6) 45.6 (16.6) 0.12 (pZ 0.137)
.1) 187.7 (38.0) 0.24 (pZ 0.003)
Table 5 Comparison of the occurrence of four different
potential side effects and their aggregate to ICS treatment
in two groups of adult patients treated with either Bude-
sonide or Fluticasone propionate in combination with LABA.
Potential side effect Budesonide
(NZ 84)
Fluticasone
propionate
(NZ 74)
P (t-test)
Mean (SEM) Mean (SEM)
Sore throat 56.2 (9.3) 95.0 (11.1) 0.013
Dry throat 75.2 (11.6) 84.8 (11.6) 0.556
Oral thrush 4.3 (3.3) 12.4 (5.5) 0.047
Skin bruises 22.9 (6.6) 32.0 (9.1) 0.424
ICS total potential
side effects
158.6 (20.5) 223.3 (25.9) 0.046
ICS administered
dose
4.0 (0.24) 8.7 (0.48) <0.001
Potential side effects steroids and b2-agonists 571report one or more of four potential side effects within the
last month of treatment.
One reason for the large difference in occurrence could
be that the registered potential side effects occur in
normal life in healthy individuals, and as such may not at all
be related to actual pharmacological treatment. That at
least a minor part of the potential side effects registered in
the present study occurs in normal life is supported by the
persistence of 10% (LABA) to 40% (ICS) of events even more
than three months after treatment stop or substantial
reduction (Fig. 2). On the other hand the significant dosee
response relationship where increased dosing is associated
with an increased occurrence of side effects suggests that
parts of the events are caused by ICS and LABA treatment.
The very significant reduction (47e99%) in occurrence of all
8 different potential side effects with treatment stop or
substantial reduction suggests that the major part of side
effects registered in the present study are in fact caused by
ICS or LABA treatment. At least for b2-agonists a previous
physiologic study18 on hand tremor in association to treat-
ment with increasing doses of a short acting b2-agonist,
showed a convincing doseeresponse relationship from
a mean baseline tremor index around 30 mm (std. 5 mm)
which increased to a mean above 50 mm (std. 10 mm) withTable 6 Comparison of the occurrence of four different
potential side effects and their aggregate to LABA treat-
ment in two groups of adult patients treated with either
Formoterol or Salmeterol in combination with ICS.
Potential side effect Formoterol
(NZ 82)
Salmeterol
(NZ 76)
P
(t-test)
Mean (SEM) Mean (SEM)
Muscle twisting 8.3 (3.4) 14.9 (5.0) 0.273
Muscle cramps 48.0 (9.2) 55.0 (9.9) 0.495
Tremor 42.3 (9.3) 38.1 (8.5) 0.741
Heart palpitations 29.3 (7.5) 22.4 (6.4) 0.477
LABA total potential
side effects
116.3 (19.8) 115.5 (16.3) 0.950
LABA administered dose 3.9 (0.23) 4.6 (0.19) 0.014a cumulative dose of salbutamol of 1600 mg in 23 patients with
asthma where almost all patients showed increased hand
tremor18 also support a significant relation between treat-
ment and the occurrence of subjective perceived sideeffects.
As such the likely explanation for the contrasting data is
that patients with a potential severe chronic disease in
medical treatment are focused on health events qualita-
tively different from their normal life as disease exacer-
bations and/or the occurrence of airway infections, while
quantitative differences in health events occurring in
normal life are difficult for the individual patient to asso-
ciate with changes in medical therapy.
As to the individual side effects the largest difference
between the present data and previously reported side
effects is the occurrence of muscular events with LABA
treatment, which has remained unknown in previous
epidemiologic studies. The present study shows that almost
40% of patients treated with LABA report one or more event
of unwillingly muscle contractions within four weeks, and
more than 60% report the occurrence of muscle cramps on
one or more occasions within four weeks, which is the
single most troublesome side effect to LABA treatment
(Table 2).
The present data with a focused and detailed question-
naire of each of eight individual potential side effects to
treatment with ICS or LABA is one example of a longitudinal
population study on pharmacologic side effects performed in
a post-marketing phase,6 that demonstrate marked differ-
ences to the results of pre-marketing studies when it comes
to side effects that are less distinctive and thus largely
escapes detection in pre-marketing studies.
The present results were obtained in an open observa-
tional study and as such the results are less reliable, where
the best results are obtained in double blinded placebo
controlled trials. Future pre-marketing studies could
provide better information by the inclusion of detailed
interviews on individual potential side effects.
Modern principles of asthma treatment focus on patient
education and individual written treatment programs to
enable the individual patient to adjust treatment to actual
symptoms. At least for the use of ICS the overall treatment
principle is to control asthma with the lowest possible dose
of inhaled corticosteroids to minimize systemic adverse
effects.1 The present data supports this notion, where the
observed potential side effects to treatment with ICS,
although potentially less dangerous to patients than
systemic effects, are clearly troublesome to individual
patients and occur in well over half of patients.
As to treatment with LABA, at least in patients with
asthma, significant associations between severe and life-
threatening asthma exacerbations and LABA treatment
have been documented, even in patients receiving
concomitant treatment with inhaled corticosteroids, in
a recent meta-analysis.19 Although the observed absolute
increases in risks remained relatively small19 the data stress
that use of LABA in treatment of asthma is complex, and
they are to be used with care.20 Our data on potential side
effects to LABA treatment focuses on increases in events
occurring in normal life, which are, as for potential side
effects to ICS, not potentially dangerous, but on the other
hand occur in a very substantial part of patients, and are
clearly troublesome to individual patients in their daily life.
Total dose LABA
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Figure 2 The change in total dose of potential side effects to treatment with ICS and LABA before and at least 3 months after
stop or significant reduction in treatment with both ICS and LABA in 31 adult patients. The mean dose of side effects to ICS
treatment was reduced from 275.6 to 105.2 or 62% (p< 0.001), while the mean dose of potential side effects to treatment with
LABA was reduced 91% (p< 0.001) from a mean of 193.2 before reduction to a mean of 17.4 after reduction in treatment.
572 J. Korsgaard, M. LedetThe present data, which shows that four out of five adult
patients treated with ICS and LABA seem to experience
some degree of side effects, although not serious, further
underlines the notions1,2 of a tailored individual treatment
of asthma and COPD to reduce treatment to the minimum
dose needed in each case.
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